{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T15:28:08Z","timestamp":1792337288289,"version":"4.4.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-025-04681-0","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T09:04:46Z","timestamp":1743066286000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Pyridostigmine-induced complete atrioventricular block in a patient with Musk antibody-negative myasthenia gravis a case report"],"prefix":"10.1186","volume":"25","author":[{"given":"Mohammad Taghi Hedayati","family":"Godarzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeed","family":"Abrotan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Fallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Seifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Novin","family":"Nikbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"issue":"9","key":"4681_CR1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","volume":"12","author":"JJ Verschuuren","year":"2013","unstructured":"Verschuuren JJ, Huijbers MG, Plomp JJ, Niks EH, Molenaar PC, Martinez-Martinez P, et al. Pathophysiology of myasthenia Gravis with antibodies to the acetylcholine receptor, muscle-specific kinase and low-density lipoprotein receptor-related protein 4. Autoimmun Rev. 2013;12(9):918\u201323.","journal-title":"Autoimmun Rev"},{"issue":"10","key":"4681_CR2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia Gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"1","key":"4681_CR3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1186\/s12967-021-03185-7","volume":"19","author":"N Salari","year":"2021","unstructured":"Salari N, Fatahi B, Bartina Y, Kazeminia M, Fatahian R, Mohammadi P, et al. Global prevalence of myasthenia Gravis and the effectiveness of common drugs in its treatment: a systematic review and meta-analysis. J Transl Med. 2021;19(1):516.","journal-title":"J Transl Med"},{"key":"4681_CR4","unstructured":"Beloor Suresh A, Asuncion RMD. Myasthenia Gravis. StatPearls. Treasure Island (FL): StatPearls publishing copyright \u00a9 2023. StatPearls Publishing LLC.; 2023."},{"key":"4681_CR5","unstructured":"Singh R, Sadiq NM. Cholinesterase inhibitors. StatPearls. Treasure Island (FL): StatPearls publishing copyright \u00a9 2023. StatPearls Publishing LLC.; 2023."},{"issue":"3","key":"4681_CR6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s13181-018-0669-1","volume":"14","author":"H Ohbe","year":"2018","unstructured":"Ohbe H, Jo T, Matsui H, Fushimi K, Yasunaga H. Cholinergic crisis caused by cholinesterase inhibitors: a retrospective nationwide database study. J Med Toxicol. 2018;14(3):237\u201341.","journal-title":"J Med Toxicol"},{"issue":"1","key":"4681_CR7","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/CND.0000000000000162","volume":"19","author":"F Nazari","year":"2017","unstructured":"Nazari F, Abdi S. Pyridostigmine-Induced bradycardia in patient with MuSK-Ab-Positive myasthenia Gravis and alopecia universalis. J Clin Neuromuscul Dis. 2017;19(1):49\u201350.","journal-title":"J Clin Neuromuscul Dis"},{"key":"4681_CR8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.12659\/AJCR.889484","volume":"14","author":"S Said","year":"2013","unstructured":"Said S, Cooper CJ, Alkhateeb H, Elhanafi S, Bizet J, Gosavi S, et al. Pyridostigmine-induced high grade SA-block in a patient with myasthenia Gravis. Am J Case Rep. 2013;14:359\u201361.","journal-title":"Am J Case Rep"},{"issue":"3","key":"4681_CR9","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","volume":"41","author":"M Pasnoor","year":"2010","unstructured":"Pasnoor M, Wolfe GI, Nations S, Trivedi J, Barohn RJ, Herbelin L, et al. Clinical findings in MuSK-antibody positive myasthenia Gravis: a U.S. Experience. Muscle Nerve. 2010;41(3):370\u20134.","journal-title":"Muscle Nerve"},{"issue":"5","key":"4681_CR10","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1253\/circj.CJ-19-0133","volume":"83","author":"K Kimura","year":"2019","unstructured":"Kimura K, Kimura T, Ishihara M, Nakagawa Y, Nakao K, Miyauchi K, et al. JCS 2018 guideline on diagnosis and treatment of acute coronary syndrome. Circ J. 2019;83(5):1085\u2013196.","journal-title":"Circ J"},{"key":"4681_CR11","doi-asserted-by":"crossref","unstructured":"Alhaidar MK, Abumurad S, Soliven B, Rezania K. Current treatment of myasthenia Gravis. J Clin Med. 2022;11(6).","DOI":"10.3390\/jcm11061597"},{"issue":"2","key":"4681_CR12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ncl.2018.01.011","volume":"36","author":"C Farmakidis","year":"2018","unstructured":"Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of myasthenia Gravis. Neurol Clin. 2018;36(2):311\u201337.","journal-title":"Neurol Clin"},{"issue":"4","key":"4681_CR13","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00131402-200306000-00006","volume":"4","author":"M Guglin","year":"2003","unstructured":"Guglin M, Campellone JV, Heintz K, Parrillo JE. Cardiac disease in myasthenia Gravis: a literature review. J Clin Neuromuscul Dis. 2003;4(4):199\u2013203.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"8","key":"4681_CR14","doi-asserted-by":"crossref","first-page":"euae212","DOI":"10.1093\/europace\/euae212","volume":"26","author":"DA Mei","year":"2024","unstructured":"Mei DA, Imberti JF, Vitolo M, Bonini N, Serafini K, Mantovani M, et al. Systematic review and meta-analysis on the impact on outcomes of device algorithms for minimizing right ventricular pacing. EP Europace. 2024;26(8):euae212.","journal-title":"EP Europace"},{"issue":"6","key":"4681_CR15","first-page":"811","volume":"7","author":"O Palmeri Nicholas","year":"2021","unstructured":"Palmeri Nicholas O, Kramer Daniel B, Karchmer Adolf W, Zimetbaum Peter J. A review of cardiac implantable electronic device infections for the practicing electrophysiologist. JACC: Clin Electrophysiol. 2021;7(6):811\u201324.","journal-title":"JACC: Clin Electrophysiol"},{"key":"4681_CR16","doi-asserted-by":"crossref","unstructured":"Imberti JF, Mei DA, Fontanesi R, Gerra L, Bonini N, Vitolo M et al. Low occurrence of infections and death in a Real-World cohort of patients with cardiac implantable electronic devices. J Clin Med. 2023;12(7).","DOI":"10.3390\/jcm12072599"},{"issue":"2","key":"4681_CR17","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/j.1540-8167.2007.00938.x","volume":"19","author":"A Gehi","year":"2008","unstructured":"Gehi A, Benatar M, Langberg J. Treatment of pyridostigmine-induced AV block with hyoscyamine in a patient with myasthenia Gravis. J Cardiovasc Electrophysiol. 2008;19(2):214\u20136.","journal-title":"J Cardiovasc Electrophysiol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04681-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-025-04681-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-025-04681-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T09:05:27Z","timestamp":1743066327000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-025-04681-0"}},"subtitle":["Pyridostigmine-ind advanced AV block in MG patient with MuSK-neg"],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4681"],"URL":"https:\/\/doi.org\/10.1186\/s12872-025-04681-0","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Babol University of Medical Sciences (Ethical code: IR.MUBABOL.HRI.REC.1402.067). Informed consent was obtained from all individual participants included in the study. All participants were informed about the purpose of the study, and they were assured that their participation was voluntary and that they could withdraw from the study at any time without consequences.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Rohani Hospital, Babol University of Medical Science.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Name of Department and Institution where work was done"}}],"article-number":"225"}}